13TH INTERNATIONAL ONCOLOYTIC VIRUS CONFERENCE

NOVEMBER 5-7, 2021
HILTON SEDONA RESORT AT BELL ROCK
TABLE OF CONTENTS

4 FRIDAY, NOVEMBER 5

16 SATURDAY, NOVEMBER 6

25 SUNDAY, NOVEMBER 7

31 INVITED SPEAKERS

35 SPONSORS
Candel is a **late clinical stage** biopharmaceutical company focused on helping patients fight cancer with **oncolytic viral immunotherapies**.

Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection.

Candel has established two oncolytic viral immunotherapy investigational medicines based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. New discovery programs are based on the HSV platform. Learn more about our innovative platform [here](#).
THURSDAY, NOVEMBER 4

7:30 – 9:30 P.M.  WELCOME RECEPTION
PORCH PATIO

FRIDAY, NOVEMBER 5

7:30 A.M. – 5 P.M.  BADGE PICK-UP
CANYON BALLROOM FOYER

7:30 – 8:30 A.M.  BREAKFAST
PROVIDED - CANYON BALLROOM FOYER

#1OVOC
Scientific Session 1: Novel Payloads and Mechanisms of Action 1
Chairpersons: John Bell, PhD and Grant McFadden, PhD

8:30 – 8:55 A.M. DAVID STOJDL, PHD
TURNSTONE BIOLOGICS
Vaccinia with IL12, CTLA-4 blockage and FLT3

8:55 – 9:20 A.M. LESLIE SHARP, PHD
ONCOMYX THERAPEUTICS
Multi-armed myxoma virus demonstrates activity in preclinical models

9:20 – 9:32 A.M. DIVYA RAVIRALA, PHD
UNIVERSITY OF HOUSTON
Oral Abstract 1
Co-delivery of Novel bi-Specific and tri-Specific Engagers by an Amplicon Vector Augments the Therapeutic Effect of a HSV-based Oncolytic Virotherapy

9:32 – 9:44 A.M. NIKOLAS MARTIN, PHD
OTTAWA HOSPITAL RESEARCH INSTITUTE
Oral Abstract 2
An oncolytic vaccinia virus encoding virus-like-particles and self-amplifying RNA replicons: Teaching new tricks to an old virus
Scientific Session 1: Novel Payloads and Mechanisms of Action 1
Chairpersons: John Bell, PhD and Grant McFadden, PhD

9:44 – 9:56 A.M.  BART SPIESSCHAE, DMV, PHD
VIRATHERAPEUTICS GMBH
Oral Abstract 3
Lymphotoxin- α-armed oncolytic VSV-GP synergizes with SMAC mimetics to induce enhanced tumor cell death and regression

9:56 – 10:08 A.M.  JOHN CHRISTIE, MS
ARIZONA STATE UNIVERSITY SCHOOL OF LIFE SCIENCES
Oral Abstract 4
Delivery and Efficacy of LIGHT-armed Myxoma Virus in a Syngeneic Lung Metastatic Murine Osteosarcoma

10:08 – 10:30 A.M.  COFFEE BREAK
**Scientific Session 2: Novel Payloads and Mechanisms of Action 2**

Chairpersons: John Bell, PhD and Grant McFadden, PhD

---

**10:30 – 10:55 A.M.**

**LEONARD SEYMOUR, PHD**

UNIVERSITY OF OXFORD

Arming oncolytic DNA viruses to improve their anticancer impact

---

**10:55 – 11:20 A.M.**

**BALVEEN KAUR, PHD**

MCGOVERN MEDICAL SCHOOL

Oncolytic Viral therapy signaling NOTCH

---

**Multiple Therapies, One Virus**

Next-Generation Oncolytic Vaccinia Virus Immunotherapy Platform

**KALIVIR** is dedicated to developing systemically deliverable next-generation oncolytic virus immunotherapies. We have designed a new class of oncolytic virus that combines the natural ability of viruses to kill cancers with novel mechanisms to stimulate anti-tumor immunity and modulate the tumor microenvironment to maximize targeted tumor killing. Our oncolytic product candidates are designed to be safe, potent and systemically deliverable across different tumor types. We are now advancing multiple therapeutic candidates toward the clinic.

**KALIVIR** has developed a novel, patent oncolytic platform called the Vaccinia Enhanced Template (VET™). Our VET™ Platform includes multiple proprietary genetic modifications that can be combined to generate unique oncolytic viruses optimized for systemic delivery and expression of therapeutic transgenes within target tumors.

Our proprietary VET™ modifications enhance vaccinia virus' systemic delivery capabilities, tumor-targeted replication, and spread within and between tumors.

**KALIVIR**'s VET™ Platform is a versatile viral backbone that can be harnessed to create novel, best-in-class oncolytic immunotherapies.

Using the VET™ Platform, we design and construct oncolytic candidates through rigorous testing and scientific evaluation to tailor each virus for the payload and the target tumor. Genetic modifications derived from the VET™ Platform operate synergistically, rather than piecewise, to enable the most effective tumor killing and immune modulation.

We have partnered with Astellas Pharma Inc. to develop our first lead candidate VET®-12 and to generate a second novel product using the VET™ Platform. We continue to seek additional development partnerships and collaboration opportunities.

To learn more about working with us, please visit [www.kalivir.com](http://www.kalivir.com)
Scientific Session 2: Novel Payloads and Mechanisms of Action 2
Chairpersons: John Bell, PhD and Grant McFadden, PhD

11:20 – 11:32 A.M.   **HAIFEI JIANG, PHD**
MAYO CLINIC
Oral Abstract 5
Herpesviral Combination Therapy For Targeting Both Cancer Cells And Cancer Associated Stromal Cells

11:32 – 11:44 A.M.   **FLURIN CAVIEZEL, MSC**
UNIVERSITY OF OXFORD
Oral Abstract 6
Targeting the Extracellular Matrix to Overcome Immunosuppression Using Bi-Specifics Delivered by Oncolytic Viruses

11:44 – 11:56 A.M.   **EMANUELE SASSO, PHD**
UNIVERSITY OF NAPLES FEDERICO
Oral Abstract 7
Arming Oncolytic Herpes Virus with Adenosine Deaminase Enzyme for Clearance of Immunosuppressive Tumor Adenosine

11:56 A.M. – 12:55 P.M.   **LUNCH**
Provided
# Scientific Session 3: Novel Combinations and Mechanisms of Action 1

Chairpersons: Martine Lamfers, PhD and Samuel Rabkin, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution/Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:55 – 1:20 P.M.</td>
<td><strong>KEVIN HARRINGTON, PHD</strong></td>
<td>THE INSTITUTE OF CANCER RESEARCH, LONDON Mechanistic studies of drug-virus combinations reveal unexpected immunotherapeutic potential</td>
</tr>
<tr>
<td>1:20 – 1:45 P.M.</td>
<td><strong>CHAE-OK YUN, PHD</strong></td>
<td>GENEMEDICINE CO., LTD. Tumor-targeted systemic delivery of oncolytic adenoviruses using nanocarrier platform</td>
</tr>
<tr>
<td>1:45 – 1:57 P.M.</td>
<td><strong>LORELLA TRIPODI</strong></td>
<td>EUROPEAN SCHOOL OF MOLECULAR MEDICINE (SEMM) Oral Abstract 8 Gut microbiome affects oncolytic adenovirus-mediated immunogenic cell death in a melanoma mouse model</td>
</tr>
<tr>
<td>1:57 – 2:09 P.M.</td>
<td><strong>MIRIAM VALENZUELA, MSC</strong></td>
<td>UNMHSC Oral Abstract 9 Tumor Necrosis Factor α plays multiple negative roles during oncolytic therapy both inhibiting systemic efficacy and exacerbating immune mediated toxicities</td>
</tr>
</tbody>
</table>
ONCOLYTIC VIRUSES
EFFECTIVE ANTICANCER DRUGS

ABOUT US

At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated.

Phase 1-2 trials with our oncolytic viruses, as monotherapies or in combination with immuno-oncology drugs, are underway in multiple cancer indications.

PLATFORMS

- Vesicular Stomatitis Virus
- Measles Virus
- Infectious Picornavirus mRNA

www.vyriad.com
Scientific Session 3: Novel Combinations and Mechanisms of Action 1

Chairpersons: Martine Lamfers, PhD and Samuel Rabkin, PhD

2:09 – 2:21 P.M. GUIDO WOLLMANN, MD
MEDICAL UNIVERSITY INNSBRUCK
Oral Abstract 10
A Modular Self-Adjuvanting Cancer Vaccine Combined With An Oncolytic Vaccine Induces Potent Antitumor Immunity

2:21 – 2:33 P.M. ZAID TAHA, MSC
OTTAWA HOSPITAL RESEARCH INSTITUTE, UNIVERSITY OF OTTAWA
Oral Abstract 11
Evaluation of Viral Sensitizing Antibody-Drug Conjugate (ADC) and Oncolytic Virus Combination Regimen in Novel Murine Models of HER2+ Cancer

2:33 – 2:45 P.M. COFFEE BREAK
Scientific Session 4: Novel Combinations and Mechanisms of Action 2
Chairpersons: Martine Lamfers, PhD and Samuel Rabkin, PhD

2:45 – 3:10 P.M.  ALAN MELCHER, PHD
THE INSTITUTE OF CANCER RESEARCH, LONDON
Oncolytic Herpes Virus and BRAF Inhibitor Therapy for Melanoma: The Role and Application of CD4 T Cell Signaling Dynamics

3:10 – 3:35 P.M.  RICHARD G. VILE, PHD
MAYO CLINIC
Combining CAR T Cell Therapy with Oncolytic Viruses

3:35 – 3:47 P.M.  JAHANARA RAJWANI
UNIVERSITY OF CALGARY
Oral Abstract 12
Oncolytic Virus Infection of Non Cancer Cells Improves Antitumour Immunity by Increasing Tumour-Antigen Specific T Cell Generation in the Lymph Node

3:47 – 3:59 P.M.  MATTHEW MULLARKEY, MD
MCGOVERN MEDICAL SCHOOL, UTHSC
Oral Abstract 13
Oncolytic HSV-P10 and Targeting of Glycolysis and Oxidative Phosphorylation as a Potential Therapy in the Treatment of Glioblastoma
Scientific Session 4: Novel Combinations and Mechanisms of Action 2
Chairpersons: Martine Lamfers, PhD and Samuel Rabkin, PhD

3:59 – 4:11 P.M.: **MOLLY HOLBROOK**
UNIVERSITY OF NORTH CAROLINA-CHARLOTTE
Oral Abstract 14
Screening of FDA-Approved Drug Library for Combinatorial Treatment of Pancreatic Cancer Cells with Oncolytic Vesicular Stomatitis Virus
Scientific Session 5: Clinical Trials
Chairpersons: E. Antonio Chiocca, MD, PhD, FAANS and Chae-Ok Yun, PhD

4:11 – 4:36 P.M.  **E. ANTONIO CHIOCCA, MD, PHD, FAANS**
Harvard Medical School
First In Human Clinical Trials of New Oncolytic Virus Expressing ICP34.5 for Glioblastoma

4:36 – 5:01 P.M.  **JOSELLE COOK, MD**
Mayo Clinic
Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies

5:01 – 5:26 P.M.  **TOMOKI TODO, PHD**
The University of Tokyo
Clinical development and approval of oncolytic herpes virus G47Δ

6 – 9:45 P.M.  **DINNER**
Shuttles provided
(Pickup at 6 P.M., return at 9:45 P.M.)
Steakhouse 89
2620 W State Rte 89A
Sedona, AZ 86336
SATURDAY, NOVEMBER 6

7:30 A.M. – 5 P.M.  BADGE PICK-UP
CANYON BALLROOM FOYER

7:30 – 8:30 A.M.  BREAKFAST
PROVIDED - CANYON BALLROOM FOYER

PsiOxus
THERAPEUTICS
Leaders in Tumor Re-engineering

Systemically Delivered Tumor Re-Engineering Vectors for Reprogramming the Tumor Microenvironment (TME) to Treat Cancer

Clinically demonstrated:
- LV vector administration (>150 pts)
- Delivery to primary and metastatic tumors
- Tumor-specific vector replication
- Long-term expression within tumor

Tumor re-engineered by vector:
- Tumor-specific production of combo therapeutics, leading to TME re-programming

Multiple therapeutic transgene payloads & combinations:
- Antibodies, bispecifics, cytokines, chemokines, immunomodulatory ligands etc

Monotherapy dosing or in combination with other IO therapies (e.g. CPIs, Cell Therapy)

TME reprogramming leads to recruitment and activation of immune cells to drive anti-tumor responses
Scientific Session 6: Novel Platforms 1
Chairperson: Noriyuki Kasahara, MD, PhD

8:30 – 8:55 A.M.  STEPHEN J. RUSSELL, MD, PHD
MAYO CLINIC
Measles Virus, Stealthed and Retargeted

8:55 – 9:07 A.M.  SARA FEOLA
UNIVERSITY OF HELSINKI
Oral Abstract 15
A Novel Immunopeptidomic-Based Pipeline for the Generation of Personalized Oncolytic Cancer Vaccines

9:07 – 9:19 A.M.  KAROL BUDZIK, PHD
MAYO CLINIC
Oral Abstract 16
Development and Characterization of a Foamy Virus-Based Oncolytic Replicating Retroviral Vector
Scientific Session 6: Novel Platforms 1
Chairperson: Noriyuki Kasahara, MD, PhD

9:19 – 9:31 A.M.  LIANG DENG, MD, PHD
MEMORIAL SLOAN KETTERING CANCER CENTER
Oral Abstract 17
Targeting Regulatory T Cells and Exhausted T Cells by a Second-Generation Recombinant Modified Vaccinai Virus Ankara

9:31 – 9:56 A.M.  YUMAN FONG, MD
CITY OF HOPE MEDICAL CENTER
Redesigning the Pox Virus for Oncolytic Therapy

9:56 – 10:15 A.M.  COFFEE BREAK
Scientific Session 7: Novel Platforms 2
Chairperson: Stephen J. Russell, MD, PhD

10:15 – 10:40 A.M.  AUTUMN SCHULZE, PHD
MAYO CLINIC
Synthetic Infectious RNA-Based Oncolytic Immunotherapy

10:40 – 10:52 A.M.  SHAUN XIALIU ZHANG, MD, PHD
UNIVERSITY OF HOUSTON
Oral Abstract 18
Novel Strategies to Modify an Oncolytic HSV for Systemic Delivery

10:52 – 11:04 A.M.  ALEXANDER HADDAD, MD
UCSF
Oral Abstract 19
A Synthetic Novel Replicating Retroviral Gene Therapy Platform for the Treatment of Glioblastoma
Scientific Session 7: Novel Platforms 2
Chairperson: Stephen J. Russell, MD, PhD

11:04 – 11:16 A.M.  VELIA PENZA, MS
MAYO CLINIC
Deletion of the polycytidine (polyC) tract in oncolytic miRNA-detargeted Mengovirus increases its therapeutic efficacy in a murine multiple myeloma model

11:16 – 11:40 A.M.  LUNCH
BOXED PICK-UP

LEADING THE FIGHT AGAINST SOLID TUMORS
Turnstone Biologics is a clinical stage biotech company developing new generations of viral and cell-based immunotherapies to provide benefit to the millions of cancer patients underserved by current treatment options.

TURNSTONE BIOLOGICS
DISCOVER MORE AT WWW.TURNSTONEBIO.COM
**Keynote Speaker Session**
Chairperson: Stephen J. Russell, MD, PhD

11:40 A.M. – 12 P.M.  **ANNOUNCEMENT OF THE GOLDEN VIRUS AWARD**

12 – 12:05 P.M.  **INTRODUCTION TO KEYNOTE SPEAKER**
STEPHEN J. RUSSELL, MD, PHD

12:05 – 1:05 P.M.  **LARRY COREY, MD**
FRED HUTCHINSON CANCER RESEARCH CENTER
The Trek Toward COVID-19 Vaccines: How We Got There and What’s Left to Accomplish

1:05 – 6 P.M.  **FREE AFTERNOON**
ACTIVITIES INCLUDE
Jeep Ride, Hike, Golf

**Special Session**
Chairperson: Kah Whye Peng, PhD and David Stojdl, PhD

6:30 – 7:00 P.M.  **WORKING DINNER**
PROVIDED
Special Session
Chairperson: Kah Whye Peng, PhD and David Stojdl, PhD

7 – 7:20 P.M.  **PAUL PETER TAK, MD, PHD**
CANDEL THERAPEUTICS
Leveraging Viral Oncolytic Immunotherapy Platform To Tip The Balance In Favor Of The Immune System

7:20 – 7:40 P.M.  **DAVID KRIGE, PHD**
PSIOXUS
Dose-dependent and Persistent Increases in Inflammatory Cytokines in Patients with Metastatic/Advanced Epithelial Cancer Following Treatment with Novel T-SiGn Vectors

7:40 PM – 8 P.M.  **STEVE THORNE, PHD**
KALIVIR THERAPEUTICS
The VET platform; re-targeting oncolytic vaccinia virus to tumors through expression of chemokine receptors

8 – 8:20 P.M.  **JAMES BURKE, MD**
CG ONCOLOGY
CG0070 a GM-CSF expression, tumor selective oncolytic adenovirus : Clinical Program Review
Special Session

8:20 – 8:32 P.M. RIANNA VANDERGAAST
IMANIS LIFE SCIENCES
Using the IMMUNO-COV Clinical Assay for SARS-CoV-2-Neutralizing Antibodies to Track Titer Declines in Individuals Following Vaccination

8:32 – 8:44 P.M. EDWARD KENNEDY, PHD
ONCORUS INC.
Systemic Intravenous Synthetic RNA Virus Immunotherapy for the Repeat Treatment of Cancer. Edward Kennedy

8:44 – 8:56 P.M. STEVE POTTS, PHD, MBA
ONCOMYX THERAPEUTICS
Benefits of a systemic-delivered, multi-armed non-human pathogen, myxoma virus, against solid and heme cancers

8:56 – 9:08 P.M. ZANE YANG, MD
DENovo BIOPHARMA
Late-stage clinical development of Toca 511
BETTER TOGETHER
Welcome IOVC Conference Attendees
We Are A Proud Diamond Sponsor.
Our myxoma platform is designed for best-in-class oncolytic immunotherapies. We want to make cancer immunotherapy and targeted treatments help more patients.
Our Team Will Be Here.

Steve Potts, PhD, MBA  
Cofounder, CEO & Director

Leslie Sharp, PhD  
Chief Scientific Officer

Grant McFadden, PhD  
Cofounder, Research Advisor, & Director

Talk and Poster Info

Session 1: Novel Payloads and Mechanisms of Action 1  
Friday, Nov. 5th from 8:55am - 9:20am MST with Leslie Sharp, PhD

Poster Presentation (Virtual)  
Friday, Nov. 5th - Sunday, Nov. 7th with Lina Franco, PhD, Scientist II, OncoMyx is available on demand

Special Session  
Saturday, Nov. 6th from 8:44pm - 8:56pm MST with Steve Potts, PhD, MBA

Live Q&A for Poster Presentation  
Sunday, Nov. 7th from 1:00pm - 3:30pm MST with Lina Franco, PhD

OncoMyx therapeutics  Learn more at www.oncomyx.com
7:30 A.M. – 5 P.M.  **REGISTRATION**  
CANYON BALLROOM FOYER

7:30 – 8:30 A.M.  **BREAKFAST**  
PROVIDED - CANYON BALLROOM FOYER

---

**CG Oncology**

Developing the Next Evolution of Oncolytic Immunotherapy

*CG Oncology* is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with urothelial cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in a Phase 3 trial with CG0070 as a monotherapy for the treatment of BCG-unresponsive NMIBC, and a combination Phase 2 study of CG0070 with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab) for the treatment of MIBC in a Phase 1b investigator-initiated trial with Moffitt Cancer Center, and a Phase 1/2 trial for the treatment of metastatic urothelial cancer.

In additional indications beyond uro-oncology, CG Oncology will evaluate the combination of CG0070 with Roche's atezolizumab in a Phase 1/2 clinical trial in patients with various advanced solid tumors. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to patients worldwide.

Learn more at www.cgoncology.com
Scientific Session 8: Clinical Trials 2
Chairpersons: Robert Coffin, PhD and Evanthia Galanis, MD

8:30 – 8:55 A.M.  ROBERT COFFIN, PHD
REPLIMUNE INC.
Next Generation Oncolytic HSV

8:55 – 9:20 A.M.  HELEN GOGAS, MD, PHD
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Amgen Phase 3 T-Vec Melanoma Trial

9:20 – 9:32 A.M.  PRAVEEN BOMMAREDY, PHD
REPLIMUNE, INC.
Oral Abstract 21
Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation

9:32 – 9:44 A.M.  SHRUTHI NAIK, PHD
MAYO CLINIC
Oral Abstract 22
Safety and Efficacy of Neoadjuvant Intravesical Oncolytic MV-NIS in Patients with Urothelial Carcinoma
Scientific Session 8: Clinical Trials 2
Chairpersons: Robert Coffin, PhD and Evanthia Galanis, MD

9:44 – 9:56 A.M.  Guy Ungerechts, MD, PhD
National Center for Tumor Diseases
Heidelberg
Oral Abstract 23
Phase 2 Trial of Oncolytic H-1 Parovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

10 – 10:30 A.M.  COFFEE BREAK

A global leader in oncolytic immunotherapeutics

“Targeting, Attacking, and Eradicating Cancers®

www.sillajen.com/eng
Scientific Session 9: Clinical Trials 3
Chairpersons: Robert Coffin, PhD and Evanthia Galanis, MD

10:30 – 10:55 A.M.  MACIEJ LESNIAK, MD
NORTHWESTERN FEINBERG SCHOOL OF MEDICINE
Neural Stem Cell Delivery of Oncolytic Virotherapy for Glioma

10:55 – 11:20 A.M.  EVANTHIA GALANIS, MD
MAYO CLINIC
First in human Testing of Measles Virus Infected Mesenchymal Stem Cells

11:20 – 11:32 A.M.  ADELSAMSON, PHD
UNIVERSITY OF LEEDS
Oral Abstract 24
Neoadjuvant Oncolytic Pexa Vec for Patients with Colorectal Cancer Liver Metastases

11:32 – 11:44 A.M.  PARKER DRYJA
UNMHSC
Oral Abstract 25
Altered Arginine Metabolism within the Tumor Microenvironment Inhibits Oncolytic Myxoma Virus Replication Preventing Effective Therapy
Scientific Session 9: Clinical Trials 3
Chairpersons: Robert Coffin, PhD and Evanthia Galanis, MD

11:44 – 11:56 A.M.  MIRIAM BAZAN-PEREGRINO, DPHIL
VCN BIOSCIENCES
Oral Abstract 26
Oncolytic Adenovirus VCN-01 Targeting the Dysfunctional Rb Pathway Is an Encouraging Therapy Against Retinoblastoma

11:56 A.M. – 12:08 P.M.  JAMES BURKE, MD
MOFFIT CANCER CENTER
Oral Abstract 27
CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

12:08 – 1:08 P.M.  LUNCH
PROVIDED
SUNDAY, NOVEMBER 7

Poster Session

1 – 3:30 P.M.  VIRTUAL POSTER PRESENTATIONS

3:30 – 3:55 P.M.  COFFEE BREAK

The Great Debate

3:55 – 4 P.M.  ANNOUNCEMENT OF CONRAD AWARD WINNERS

4 – 5:30 P.M.  JOHN BELL VS. NORIYUKI KASHARA
MODERATOR: STEPHEN J. RUSSELL, MD, PHD
Complex large viruses are superior to small elegant viruses

7 – 9:30 P.M.  FAREWELL DINNER
CANYON BALLROOM

#IOVC
E. ANTONIO CHIOCCA, M.D., PH.D., FAANS
Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School. Established by the Daniel E. Ponton Fund. Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women’s Hospital

Neural Stem Cell Delivery of Oncolytic Virotherapy for Glioma
I will be discussing the use of stem cells for virotherapy of cancer.

Disclosures
Patent, Stocks, and Consulting in Calidi Pharmaceuticals

JOSELLE COOK, MD
Oncology and Hematology Fellow Mayo Clinic, Division of Hematology

Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies
In this talk, I will discuss preliminary results and clinical activity of the Phase 1 clinical trial of systemic VSV-IFNβ-NIS administered to patients with relapsed and refractory hematologic malignancies

Disclosures
I have nothing to disclose

ROBERT COFFIN, PHD
President and Chief R&D Officer Replimune Inc

Next Generation Oncolytic HSV
An overview of the HSV-based platform being developed by Replimune will be presented, including the clinical strategy and clinical data to date

Disclosures
Shareholder & employee of Replimune Inc.

LARRY COREY, MD
PI, COVID-19 Prevention Network (CoVPN) Operations Center / Fred Hutchinson Cancer Research Center

The Trek Toward COVID-19 Vaccines: How We Got There and What’s Left to Accomplish
Dr. Corey will provide insight on the public-private partnerships utilized in the US Government program for COVID-19 vaccine development. He will overview the status of COVID-19 vaccine research, outline the conceptual framework for COVID-19 vaccine development, and offer some personal reflections. Dr. Corey will also provide interpretation on the emergence of SARS-CoV-2 variants and their impact on vaccine effectiveness.

Disclosures
I have nothing to disclose
YUMAN FONG, MD  
Sangiacomo Chair and Chairman,  
Dept of Surgery  
City of Hope Medical Center  

Redesigning the Pox Virus for Oncolytic Therapy  
This talk will discuss development of a new family of Chimeric pox viruses for use as oncolytic therapies.  

Disclosures  
Scientific Advisor: Imugene, XDemics, Eureka, PhageNova Bio, Salary and Stock; Boehringer Ingelheim, PhageNova Bio, Salary; Safety Monitor: Sangamo Royalties: Imugene, XDemics, Merck

EVANTHIA GALANIS, MD  
Sandra J. Schulze Professor of Novel Therapeutics, Professor of Oncology  
Mayo Clinic  

First in human Testing of Measles Virus Infected Mesenchymal Stem Cells  

Disclosures  
Advisory Board Gradalis, Inc. (personal compensation) Kiyatec, Inc. (personal compensation) Grant/Research/Clinical Trial Funding (to Mayo) Servier Pharmaceuticals LLC (formerly Agios Pharmaceuticals, Inc.) Celgene MedImmune, Inc. Tacon Pharmaceuticals

HELEN GOGAS, MD, PHD  
Professor in Medical Oncology, National and Kapodistrian University of Athens, Head of the 1st Department of Medicine, Laikon General Hospital  

Amgen Phase 3 T-Vec Melanoma Trial  
The scientific rationale of the combination with early phase 1b results and results of the dual primary endpoint in the phase 3 study

Disclosures  
BMS, Advisory Board, Personal; BMS, Invited Speaker, Personal; MSD, Advisory Board, Personal; MSD, Invited Speaker, Personal; NOVARTIS, Invited Speaker, Personal; PIERRE FABRE, Advisory Board, Personal; PIERRE FABRE, Invited Speaker, Personal; AMGEN, Steering Committee Member, No financial interest; AMGEN, Local PI, Institutional, Financial interest; BMS, Research Grant, Institutional, Financial interest; BMS, Local PI, Institutional, Financial interest; MSD, Local PI, Institutional, Financial interest; PFIZER, Research Grant, Institutional, Financial interest

All speaker titles, descriptions, and disclosures are provided by the speakers and details are not confirmed by ASGCT, IOVC, or the organizing committee. Some talk descriptions have been edited for length.
KEVIN HARRINGTON, PHD
Professor in Biological Cancer Therapies
The Institute of Cancer Research, London

Mechanistic studies of drug-virus combinations reveal unexpected immunotherapeutic potential
As part of a drug screen for synthetic lethal partners with oncolytic reovirus (double-stranded RNA virus), we uncovered unexpected hits related to cdk4/6 inhibition and PARP inhibition.

Disclosures
Amgen (Consultancy), Arch Oncology (Advisory Board), AstraZeneca (Research grant), Boehringer-Ingelheim (Research grant, Advisory Board), BMS (Advisory Board), Codik (Advisory Board), Inzen (Advisory Board), Merck-Serono (Advisory Board), Merck-Sharp-Dohme (Advisory Board, Research grant), Replimune (Advisory Board, Research grant), Oncolys (Advisory Board).

MACIEJ S. LESNIAK, MD
Professor and Chair, Department of Neurological Surgery
Northwestern Feinberg School of Medicine

Neural Stem Cell Delivery of Oncolytic Virotherapy for Glioma
I will be discussing the use of stem cells for virotherapy of cancer.

Disclosures
Patent, Stocks, and Consulting in Calidi Pharmaceuticals

BALVEEN KAUR, PHD
Professor
McGovern Medical School

Oncolytic Viral therapy signaling NOTCH
Effect of oncolytic HSV-1 on NOTCH signaling will be presented. The effect of oHSV induced NOTCH activation on tumor extracellular environment and its impact on immunotherapy will be discussed.

Disclosures
N/A

ALAN MELCHER, PHD
Professor of Translational Immunotherapy
The Institute of Cancer Research, London

Oncolytic herpes virus and BRAF inhibitor therapy for melanoma: the role and application of CD4 T cell signalling dynamics
Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represents a promising immunotherapy for the treatment of BRAF mutant cancers, and can be improved by the further addition of immune checkpoint inhibitor (ICI) antibodies.

Disclosures
Grant/Research support from Oncolytics Biotech Inc, AZ, BMS Honoraria from: Amgen, BMS, Merck Serono, Turnstone Biologics
LEN SEYMOUR, PHD
Professor of Gene Therapies
University of Oxford

Arming oncolytic DNA viruses to improve their anticancer impact
Bispecific antibodies provide tremendous opportunity for HLA-independent killing of cancer cells by endogenous T cells, a strategy that complements direct oncolysis well, particularly if two distinct mechanisms of cancer selectivity are used.

Disclosures
I am a paid consultant to Psioxus Therapeutics

AUTUMN J. SCHULZE, PHD
Assistant Professor of Molecular Medicine
Mayo Clinic

Synthetic Infectious RNA-Based Oncolytic Immunotherapy
This talk will discuss the formulation of targeted oncolytic picornaviruses as infectious RNA, the ability to scale manufacturing, therapeutic efficacy, immune activation, and the capacity to be packaged within lipid nanoparticles.

Disclosures
Vyriad; Sponsored Research Agreement Funding and Technology Intellectual Property Royalty

LESLIE SHARP, PHD
CSO
OncoMyx Therapeutics

Multi-armed myxoma virus demonstrates activity in preclinical models
Multi-armed myxoma virus is under investigation as a novel immunomodulatory cancer therapeutic. Oncolytic activity and transgene production capability were examined in multiple cancer cell lines. In vivo efficacy following intratumoral and intravenous administration of multi-armed myxoma virus, both alone and with immune checkpoint inhibitors is demonstrated.

Disclosures
OncoMyx Therapeutics; Salary and Stock Options

All speaker titles, descriptions, and disclosures are provided by the speakers and details are not confirmed by ASGCT, IOVC, or the organizing committee. Some talk descriptions have been edited for length.
RICHARD G. VILE, PHD  
Professor of Immunology  
Mayo Clinic  
Combining CAR T Cell Therapy with Oncolytic Viruses  
Oncolytic viruses are excellent candidates to combine with adoptive T cell therapies due their potential inflammatory properties which can convert immune cold tumors into immune hot, inflamed tumors. However, we have shown that not all heat is equal, especially for activated T cells. In this presentation we will present our studies on how the combination of CAR T cells and OV needs to be carefully timed and structured for optimal synergy between the two modalities.  
Disclosures  
RGV has received research funding for projects from Vyriad, and Oncolytics Biotech.

DAVID STOJDL, PHD  
Senior Vice President Research  
Turnstone Biologics  
Vaccinia with IL12, CTLA-4 blockage and FLT3  
Disclosures  
I am the co-founder of Turnstone Biologics

TOMOKI TODO, PHD  
Professor  
Division of Innovative Cancer Therapy and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo  
Clinical development and approval of oncolytic herpes virus G47Δ  
G47Δ is a triple-mutated, third-generation oncolytic HSV-1 that exhibits enhanced replication capability in a variety of cancer, efficient induction of specific antitumor immunity, and high safety features.  
Disclosures  
I own the patent right for G47Δ in multiple countries including Japan.

CHAE-OK YUN, PHD  
Professor, Hanyang University & CEO, GeneMedicine Co., Ltd.  
Tumor-targeted systemic delivery of oncolytic adenoviruses using nanocarrier platform  
Despite rapid growth in the number of oncolytic viruses (OVs) entering clinical trials recently, there are several inherent limitations that are critical barriers to maximizing their therapeutic potential in cancer therapy applications.  
Disclosures  
I am CEO of GeneMedicine Co., Ltd.
Thank you to our sponsors for their support:

DIAMOND

CANDEL THERAPEUTICS
OncoMyx Therapeutics
Replimune

VIYRIAD

GOLD

GENEMEDICINE
KALIVIR IMMUNOTHERAPEUTICS

SILVER

CG ONCOLOGY
PsiOxus THERAPEUTICS
SILLAJEN
TURNSTONE BILOGICS

BRONZE

Imanis LIFE SCIENCES
PALL CORPORATION

# I O V C
GeneMedicine Co., Ltd. is a research-based biotechnology company focused on developing and commercializing tumor-targeted and systemically deliverable oncolytic adenovirus for the treatment of intractable cancers. These state-of-the-art technologies are the achievement of 25 years of extensive and rigorous R&D. Since the establishment in 2014, GeneMedicine has reached two licensing-out agreements with two U.S. biotech companies and received investment of 43 million dollar (USD) to date. Our oncolytic viruses replicate and selectively destroy cancer cells. Oncolytic virus-mediated destruction of cancer cells induces a systemic antitumor immune response, which can destroy metastases at the distal sites. This makes oncolytic viruses promising next-generation cancer therapeutics. Importantly, we have developed a tumor-targeted systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system. These technologies differentiate GeneMedicine from any competitors in the global oncolytic virus therapy market.

Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms. New discovery programs are based on the HSV platform.

CAN-2409, Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells.

CAN-3110 is an HSV replication-competent oncolytic virus that selectively expresses ICP34.5, a key gene in HSV replication, in tumor cells that overexpress nestin, a cytoskeletal protein. Nestin is highly expressed in high-grade glioma cells.
KaliVir is a pioneering and science-driven company dedicated to developing novel, next-generation oncolytic virus immunotherapies. Our proprietary Vaccinia Enhanced Template (VETTM) platform employs multiple proprietary genetic modifications that can be combined to generate unique oncolytic viruses that are optimized for systemic delivery and expression of therapeutic transgenes within target tumors. In 2020, we have partnered with Astellas Pharma Inc. to develop our first lead candidate VET2-L2 and to generate a second novel product using the VETTM platform. We continue to expand our product pipeline using the VETTM platform, and are now advancing multiple therapeutic candidates toward the clinic. KaliVir is located in Pittsburgh, Pennsylvania. www.kalivir.com.

OncoMyx Therapeutics is advancing oncolytic immunotherapies with the goal of achieving the greatest therapeutic benefit for more cancer patients. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have the potential to be a safe and effective complement to immunotherapies. OncoMyx has assembled the top immuno-oncology team to develop oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response with the goal of better treating a wide range of cancers. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University. For more info, visit www.oncomyx.com.

All sponsor descriptions are provided by sponsors, and details are not confirmed by ASGCT, IOVC, or the organizing committee.
Replimune is pioneering a new class of oncolytic immunotherapies (OI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to directly kill tumors and generate systemic anti-cancer immune responses. Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma -- and is also being tested in other tumor types, including anti-PD1 failed non-small cell lung cancer. Two further product candidates, RP2 and RP3, are currently in Phase 1 clinical development. Replimune has completed buildout of its state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products.

Established in 2015, Vyriad is an oncolytic virotherapy powerhouse with a proven track record in the execution of multicenter OV clinical trials and in the creation and translational advancement of highly novel viral platforms and designs. Our in-house GMP manufacturing capability in Rochester Minnesota allows us to rapidly translate our exciting pipeline of products. We are driven by our mission to make a long-standing positive impact on the future of cancer treatment using engineered viruses. Join our dynamic team today! Contact us at https://vyriad.com/careers to learn more.

All sponsor descriptions are provided by sponsors, and details are not confirmed by ASGCT, IOVC, or the organizing committee.